132 related articles for article (PubMed ID: 1861540)
1. Serum erythropoietin concentrations in patients with myelodysplastic syndromes.
Aul C; Arning M; Runde V; Schneider W
Leuk Res; 1991; 15(7):571-5. PubMed ID: 1861540
[TBL] [Abstract][Full Text] [Related]
2. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
Bowen DT; Jacobs A; Cotes PM; Lewis TC
Eur J Haematol; 1990 Jan; 44(1):30-2. PubMed ID: 2307217
[TBL] [Abstract][Full Text] [Related]
3. Circulating erythropoietin in patients with myelodysplastic syndromes.
Jacobs A; Janowska-Wieczorek A; Caro J; Bowen DT; Lewis T
Br J Haematol; 1989 Sep; 73(1):36-9. PubMed ID: 2803975
[TBL] [Abstract][Full Text] [Related]
4. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
5. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.
Suzuki T; Oh I; Ohmine K; Meguro A; Mori M; Fujiwara S; Yamamoto C; Nagai T; Ozawa K
Int J Hematol; 2015 Jan; 101(1):32-6. PubMed ID: 25374009
[TBL] [Abstract][Full Text] [Related]
6. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
Bowen DT; Culligan D; Beguin Y; Kendall R; Willis N
Leukemia; 1994 Jan; 8(1):151-5. PubMed ID: 8289479
[TBL] [Abstract][Full Text] [Related]
7. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.
Boyko O; Simonova M; Knysh N; Danysh O; Vygovska Y; Masliak Z
Exp Oncol; 2021 Mar; 43(1):41-45. PubMed ID: 33785713
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.
Pasqualetti P; Collacciani A; Casale R
Eur Rev Med Pharmacol Sci; 2000; 4(5-6):111-5. PubMed ID: 11710507
[TBL] [Abstract][Full Text] [Related]
10. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
11. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
12. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes.
Piedras J; Hernández G; López-Karpovitch X
Am J Hematol; 1998 Feb; 57(2):113-8. PubMed ID: 9462542
[TBL] [Abstract][Full Text] [Related]
13. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
15. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis.
Bowen D; Ehmer B; Neubert P; Lewis T; Jacobs A
Exp Hematol; 1991 Aug; 19(7):613-6. PubMed ID: 1716588
[TBL] [Abstract][Full Text] [Related]
16. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
Valent P
Leuk Res; 2008 Sep; 32(9):1333-7. PubMed ID: 18417212
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
18. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
Nakazaki K; Nannya Y; Kurokawa M
Int J Hematol; 2014 Jan; 99(1):53-6. PubMed ID: 24307517
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes.
Mittelman M; Gardyn J; Carmel M; Malovani H; Barak Y; Nir U
Leuk Res; 1996 Jun; 20(6):459-66. PubMed ID: 8709617
[TBL] [Abstract][Full Text] [Related]
20. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]